GlassScriptPhysician profile
Thomas J Izquierdo
NPI 1649369554
$78,110.05
in general payments reported to CMS, 2019-2025
26 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,075 · 2020: $4,923 · 2021: $17K · 2022: $16K · 2023: $8,980 · 2024: $13K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $4,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,250.00 |
| Food and Beverage | $4,773.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $60,598.07 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $6,260.39 | 2019-2024 | Linzess |
| Allergan, INC. | $3,805.43 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,369.21 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Ardelyx, INC. | $774.77 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $721.34 | 2019-2024 | Entyvio |
| Pfizer INC. | $527.32 | 2019-2025 | |
| Intra-Sana Laboratories | $299.58 | 2022-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Gilead Sciences, INC. | $297.35 | 2019-2021 | |
| Redhill Biopharma INC. | $222.61 | 2020-2022 | |
| Celgene Corporation | $195.26 | 2023-2024 | Zeposia |
| Insmed, INC. | $143.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $141.95 | 2024 | Zeposia |
| Madrigal Pharmaceuticals | $123.26 | 2025 | Rezdiffra |
| Celltrion USA INC. | $116.40 | 2025 | Zymfentra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Concordia Pharmaceuticals INC. | $90.39 | 2019 | |
| Intercept Pharmaceuticals, INC. | $71.25 | 2020-2022 | |
| Qol Medical, LLC | $64.40 | 2019 | |
| Shionogi INC | $58.50 | 2019 | |
| Olympus America INC. | $54.67 | 2019-2024 | Single Use Electrosurgical Snare Sd-400 |
| Cumberland Pharmaceuticals, INC. | $51.72 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $33.88 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $33.22 | 2019 | |
| Genzyme Corporation | $20.71 | 2023 | |
| Nestle Healthcare Nutrition INC. | $19.87 | 2022 | |
| Alfasigma USA, INC. | $14.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Izquierdo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.